JPMorgan raises CG Oncology stock price target on trial data
JPMorgan raised its price target for CG Oncology (CGON) to $113 from $96, citing positive trial data and regulatory updates. The stock, currently at $84.78, has surged over 104% year-to-date. JPMorgan increased its success probability for Creto in bladder cancer treatments, projecting $1.2B and $1.0B in U.S. peak sales by 2037 for different settings. RBC Capital downgraded CGON to Sector Perform but raised its target to $97.
How this was made
The 30-second read
Why it matters
The key trading takeaway is the model update: JPMorgan increased probability of success in specific settings and raised risk-adjusted peak sales assumptions, resulting in a higher $113 target while keeping an Overweight rating.
Market read
A sell-side target increase with explicit trial-linked DCF inputs can drive near-term trading flows, but the magnitude of prior run-up and competing analyst views may limit follow-through.
What to watch
RBC’s concurrent downgrade to Sector Perform suggests the market may be split on how much the new read-through should de-risk the program, increasing volatility around further trial/regulatory milestones.
Background
CG Oncology is being evaluated on creto trial readouts, with JPMorgan updating its DCF assumptions after an intermediate-risk readout and a regulatory update.
Ticker impact
JPMorgan raised CG Oncology’s price target to $113 from $96 after an intermediate-risk readout and a regulatory update tied to its creto trial.
Likely upward bias as traders price in improved trial/regulatory read-through, though upside may be capped if expectations are already elevated.
The article is a fresh sell-side target change with explicit model inputs (probability of success, risk-adjusted peak sales) and a new $113 target, which can drive incremental flows. However, it is still analyst-driven rather than a new primary clinical/regulatory disclosure.
Market effects
Reinforces positive sentiment for bladder cancer oncology names tied to intermediate-risk read-throughs, potentially lifting peer sentiment even without new peer-specific catalysts.
Limited direct regional impact; primarily a US biotech sentiment/positioning signal.
Modest global relevance as it is a single-company analyst model update rather than a cross-market regulatory or trial headline.
Counterpoint
The stock has already surged over 104% YTD, so the incremental target raise may be less impactful than the market’s prior expectations; valuation concerns could dominate.
Key entities
- companyCG Oncology
NASDAQ-listed biotech whose creto trial read-through prompted JPMorgan to raise its price target.
- analyst_firmJPMorgan
Raised CG Oncology’s price target to $113 from $96 and maintained Overweight.
- analyst_firmRBC Capital
Downgraded CG Oncology to Sector Perform from Outperform despite raising its target to $97.
- clinical_trialPIVOT-6 trial
Intermediate-risk readout referenced as part of the rationale for JPMorgan’s updated assumptions.



